25603 Improvement in scalp psoriasis and quality of life with apremilast in patients with moderate to severe scalp psoriasis regardless of prior systemic treatment: Results from the phase 3, randomized STYLE study

Document Type

Conference Proceeding

Publication Date


Publication Title

J Am Acad Dermatol


Background: Apremilast 30 mg BID (APR) provided greater improvements in scalp psoriasis and quality of life vs placebo (PBO) in a phase 3 study in patients with moderate-to-severe plaque psoriasis of the scalp. We present subgroup analyses based on systemic treatment history.

Methods: Patients with moderate-to-severe scalp psoriasis (Scalp Physician’s Global Assessment ≥3, psoriasis-involved scalp surface area [SSA] ≥20%) and moderate-to-severe plaque psoriasis with inadequate response/intolerance to ≥1 topical therapy were randomized to double-blind APR or PBO for 16 weeks. SSA (last observation carried forward) and Dermatology Life Quality Index (DLQI; multiple imputation) changes were analyzed by ANCOVA in intent-to-treat (ITT) population subgroups based on prior systemic treatment.

Results: 303 patients were randomized to APR (ITT: 201; prior systemic: 99; no prior systemic: 102) or PBO (ITT: 102; prior systemic: 49; no prior systemic: 53). Mean baseline assessments were similar with APR vs PBO for SSA involvement and DLQI: SSA - Prior systemic: 61.9% vs 56.2% - No prior systemic: 61.8% vs 60.0% DLQI - Prior systemic: 13.3 vs 12.8 - No prior systemic: 12.0 vs 12.5 At Week 16, APR patients achieved greater improvements vs PBO (least-squares mean differences): SSA - Prior systemic: −27.3%, P =.0003 - No prior systemic: −33.6%, P ˂.0001 DLQI - Prior systemic: −3.4, P =.0003 - No prior systemic: −2.6, P =.0016.

Conclusions: APR demonstrated a consistent treatment effect vs PBO in moderate-to-severe scalp psoriasis patients with and without a history of prior systemic treatment.







First Page